Ramipril did not change Aβ levels in CSF [53], whereas ARBs showed a significant reduction of tau and p-tau among patients with mild cognitive impairment (MCI) [54] and reduced age-related decrease of CSF Aβ-42 in healthy patients after 24 months of treatment compared to other antihypertensive drugs [51]. Here, MAPT is linked to Cognitive impairment.